Baseline characteristics for the 45 patients, also stratified according to the GEP or FISH risk groups
| Variable . | Category . | Total (n = 45) . | GEP70 (n = 45) . | FISH (n = 44) . | GEP15 (n = 45) . | |||
|---|---|---|---|---|---|---|---|---|
| Standard-risk (n = 38) . | High-risk (n = 7) . | Standard-risk (n = 34) . | High-risk (n = 10) . | Standard-risk (n = 35) . | High-risk (n = 10) . | |||
| Age, y | Median (Q1, Q3) | 61.0 (43, 77) | 59.5 (43, 77) | 61.0 (53, 71) | 60.3 (43, 77) | 61.2 (55, 67) | 61.0 (53.0, 68.0) | 60.0 (56.0, 66.5) |
| Sex | Male | 29 (64) | 27 (71) | 2 (29) | 23 (67) | 6 (60) | 23 (65.7) | 6 (60.0) |
| ISS (n = 43) | Stage I | 13 (30) | 12 (32) | 1 (17) | 11 (33) | 2 (22) | 9 (26.5) | 4 (44.4) |
| Stage II | 21 (49) | 19 (51) | 2 (33) | 16 (49) | 5 (56) | 19 (55.9) | 2 (22.2) | |
| Stage III | 9 (21) | 6 (16) | 3 (50) | 6 (18) | 2 (22) | 6 (17.6) | 3 (33.3) | |
| ECOG PS | 0 | 18 (40) | 17 (45) | 1 (14) | 14 (41) | 4 (40) | 14 (40.0) | 4 (40.0) |
| 1 | 21 (47) | 16 (42) | 5 (71) | 16 (47) | 4 (40) | 16 (45.7) | 5 (50.0) | |
| 2 | 6 (13) | 5 (13) | 1 (14) | 4 (12) | 2 (20) | 5 (14.3) | 1 (10.0) | |
| Bone disease | Yes | 29 (64) | 23 (61) | 6 (86) | 23 (67) | 5 (50) | 23 (65.7) | 6 (60.0) |
| FISH (n = 44)* | Standard-risk | 34 (77) | 32 (84) | 2 (33) | — | — | 30 (88.2) | 4 (40.0) |
| High-risk | 10 (23) | 6 (16) | 4 (67) | — | — | 4 (11.8) | 6 (60.0) | |
| β2-microglobulin, μg/mL | Median (Q1, Q3) | 3.6 (2.5, 4.8) | 3.6 (2.3, 4.5) | 5.1 (2.8, 7.1) | 3.5 (2.3, 4.8) | 3.6 (2.8, 4.3) | 3.6 (2.5, 4.7) | 3.1 (2.3, 5.6) |
| C-reactive protein, mg/dL | Median (Q1, Q3) | 0.5 (0.1, 1.1) | 0.5 (0.1, 0.8) | 2.0 (0.7, 2.9) | 0.5 (0.1, 0.9) | 0.5 (0.4, 1.9) | 0.4 (0.1, 0.9) | 0.6 (0.5, 1.8) |
| Lactate dehydrogenase, U/L | Median (Q1, Q3) | 147.0 (121, 188) | 147.0 (120, 176) | 192.0 (142, 270) | 147.0 (121, 168) | 172.5 (124, 219) | 147.0 (122.0, 180.0) | 147.0 (97.0, 191.0) |
| Serum M spike, g/dL | Median (Q1, Q3) | 3.4 (2.5, 5.1) | 3.3 (2.5, 4.9) | 4.5 (3.2, 5.4) | 3.2 (2.3, 5.2) | 4.8 (3.5, 5.1) | 3.2 (2.2, 5.2) | 4.6 (3.6, 4.9) |
| Albumin, g/dL† | Median (Q1, Q3) | 3.6 (3.0, 4.0) | 3.6 (3.1, 4.0) | 3.3 (2.8, 3.7) | 3.7 (3.2, 4.0) | 3.1 (2.8, 3.3) | 3.7 (3.1, 4.0) | 3.4 (2.7, 3.9) |
| Creatinine, mg/dL | Median (Q1, Q3) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) | 1.3 (1.0, 1.8) | 1.1 (0.9, 1.2) | 1.2 (0.8, 1.4) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.4) |
| Hemoglobin, g/dL | Median (Q1, Q3) | 10.8 (9.7, 11.9) | 11.0 (9.8, 12.0) | 9.9 (9.3, 10.9) | 11.1 (10.1, 12.2) | 9.9 (9.2, 11.5) | 10.8 (9.6, 11.9) | 10.6 (9.8, 11.9) |
| Variable . | Category . | Total (n = 45) . | GEP70 (n = 45) . | FISH (n = 44) . | GEP15 (n = 45) . | |||
|---|---|---|---|---|---|---|---|---|
| Standard-risk (n = 38) . | High-risk (n = 7) . | Standard-risk (n = 34) . | High-risk (n = 10) . | Standard-risk (n = 35) . | High-risk (n = 10) . | |||
| Age, y | Median (Q1, Q3) | 61.0 (43, 77) | 59.5 (43, 77) | 61.0 (53, 71) | 60.3 (43, 77) | 61.2 (55, 67) | 61.0 (53.0, 68.0) | 60.0 (56.0, 66.5) |
| Sex | Male | 29 (64) | 27 (71) | 2 (29) | 23 (67) | 6 (60) | 23 (65.7) | 6 (60.0) |
| ISS (n = 43) | Stage I | 13 (30) | 12 (32) | 1 (17) | 11 (33) | 2 (22) | 9 (26.5) | 4 (44.4) |
| Stage II | 21 (49) | 19 (51) | 2 (33) | 16 (49) | 5 (56) | 19 (55.9) | 2 (22.2) | |
| Stage III | 9 (21) | 6 (16) | 3 (50) | 6 (18) | 2 (22) | 6 (17.6) | 3 (33.3) | |
| ECOG PS | 0 | 18 (40) | 17 (45) | 1 (14) | 14 (41) | 4 (40) | 14 (40.0) | 4 (40.0) |
| 1 | 21 (47) | 16 (42) | 5 (71) | 16 (47) | 4 (40) | 16 (45.7) | 5 (50.0) | |
| 2 | 6 (13) | 5 (13) | 1 (14) | 4 (12) | 2 (20) | 5 (14.3) | 1 (10.0) | |
| Bone disease | Yes | 29 (64) | 23 (61) | 6 (86) | 23 (67) | 5 (50) | 23 (65.7) | 6 (60.0) |
| FISH (n = 44)* | Standard-risk | 34 (77) | 32 (84) | 2 (33) | — | — | 30 (88.2) | 4 (40.0) |
| High-risk | 10 (23) | 6 (16) | 4 (67) | — | — | 4 (11.8) | 6 (60.0) | |
| β2-microglobulin, μg/mL | Median (Q1, Q3) | 3.6 (2.5, 4.8) | 3.6 (2.3, 4.5) | 5.1 (2.8, 7.1) | 3.5 (2.3, 4.8) | 3.6 (2.8, 4.3) | 3.6 (2.5, 4.7) | 3.1 (2.3, 5.6) |
| C-reactive protein, mg/dL | Median (Q1, Q3) | 0.5 (0.1, 1.1) | 0.5 (0.1, 0.8) | 2.0 (0.7, 2.9) | 0.5 (0.1, 0.9) | 0.5 (0.4, 1.9) | 0.4 (0.1, 0.9) | 0.6 (0.5, 1.8) |
| Lactate dehydrogenase, U/L | Median (Q1, Q3) | 147.0 (121, 188) | 147.0 (120, 176) | 192.0 (142, 270) | 147.0 (121, 168) | 172.5 (124, 219) | 147.0 (122.0, 180.0) | 147.0 (97.0, 191.0) |
| Serum M spike, g/dL | Median (Q1, Q3) | 3.4 (2.5, 5.1) | 3.3 (2.5, 4.9) | 4.5 (3.2, 5.4) | 3.2 (2.3, 5.2) | 4.8 (3.5, 5.1) | 3.2 (2.2, 5.2) | 4.6 (3.6, 4.9) |
| Albumin, g/dL† | Median (Q1, Q3) | 3.6 (3.0, 4.0) | 3.6 (3.1, 4.0) | 3.3 (2.8, 3.7) | 3.7 (3.2, 4.0) | 3.1 (2.8, 3.3) | 3.7 (3.1, 4.0) | 3.4 (2.7, 3.9) |
| Creatinine, mg/dL | Median (Q1, Q3) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) | 1.3 (1.0, 1.8) | 1.1 (0.9, 1.2) | 1.2 (0.8, 1.4) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.4) |
| Hemoglobin, g/dL | Median (Q1, Q3) | 10.8 (9.7, 11.9) | 11.0 (9.8, 12.0) | 9.9 (9.3, 10.9) | 11.1 (10.1, 12.2) | 9.9 (9.2, 11.5) | 10.8 (9.6, 11.9) | 10.6 (9.8, 11.9) |